Skip to main content
Equibles

ZIMLAB · Zim Laboratories Limited

Use ZIMLAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZIMLAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
141.70 INR +1.00 (+0.71%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 1325 Avg daily vol (3M) 10.25K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close141.70 INR Open140.70 INR Day139.70–143.40 INR 52W close59.87–152.35 INR Avg vol 30d12K Last earningsNov 5, 2026 DataDec 2022–Nov 2026

Raw chart and full-history price indicators begin at the captured split on Dec 22, 2022; bars on opposite sides are not compared.

Latest documents

2026
Nov 5
Earnings call
Quarter 2 operating income rose 19% as EU-GMP clarifications remain pending

Zim Laboratories reported Quarter 2 FY '27 total operating income of approximately Rs. 1,054 million, up 19% year-on-year. EBITDA was approximately Rs. 77 million at a 7.3% margin, while EU-GMP CAPA clarifications were being addressed.

4 source passages
Zim Laboratories Limited’s Earnings Conference Call for the 2nd Quarter and Half Year Ended September 30, 2026. For Quarter 2, Financial Year ‘27, the company reported total operating income of approximately Rs. 1,054 million, representing a year-on-year growth of 19% and sequential growth of 12%. EBITDA for the quarter stood at approximately Rs. 77 million, translating to an EBITDA margin of 7.3% compared to Rs. 34 million and a margin of 3.7% in quarter 1, 2027, an improvement of 365 basis points, driven by better topline performance. And within a few days, we will be responding with our set of documents on the clarifications that are being asked for. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲0% 963.30M INR 40.01M INR '25 Q3 ▼7.7% 1.09B INR 48.85M INR '25 Q4 ▼12.3% 717.56M INR −18.75M INR '26 Q1 ▼3.7% 887.11M INR −4.25M INR '26 Q2 ▲12.8% 1.09B INR 43.98M INR '26 Q3 ▼3.2% 1.05B INR 37.40M INR '26 Q4 ▲31.2% 941.78M INR −40.17M INR '27 Q1 LATEST ▲18.9% 1.05B INR −20.49M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 59.87 INR Now 141.70 INR · 88% Range high 152.35 INR
vs 200-day avg +35% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

Raw-price comparisons begin at the captured split on Dec 22, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
XBOM:ZIMLAB +7.5% +1.3% +41.7% +3.9% +97.1%

Exchange listing

Market
XBOM
Ticker
ZIMLAB
ISIN
INE518E01015
Security
Ordinary share
Trading currency
INR

Company

Website
https://zimlab.in/
Investor relations
https://zimlab.in/investors

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-05 Transcript
    Earnings Call
  • Earnings call · Q1 2027 2026-08-07 Transcript
    Earnings Call
  • Earnings call · Q4 2026 2026-05-20 Transcript
    Earnings Call for the Quarter Ended March 31, 2026